Sotera Health (NASDAQ:SHC) Releases FY 2026 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.930-1.01 for the period, compared to the consensus earnings per share estimate of 0.910. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SHC shares. Citigroup upped their price objective on Sotera Health from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. lifted their price objective on Sotera Health from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada initiated coverage on shares of Sotera Health in a research report on Thursday, January 8th. They set an “outperform” rating and a $24.00 target price for the company. BMO Capital Markets initiated coverage on shares of Sotera Health in a report on Thursday, November 13th. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, Barclays raised their target price on shares of Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.43.

Sotera Health Stock Down 3.2%

Shares of NASDAQ SHC opened at $16.18 on Thursday. The stock’s 50-day simple moving average is $17.98 and its 200-day simple moving average is $16.83. The firm has a market cap of $4.60 billion, a price-to-earnings ratio of 59.93 and a beta of 1.82. The company has a debt-to-equity ratio of 3.51, a quick ratio of 2.18 and a current ratio of 2.46. Sotera Health has a 1 year low of $9.53 and a 1 year high of $19.85.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. The firm had revenue of $303.44 million for the quarter, compared to analysts’ expectations of $300.68 million. Sotera Health had a net margin of 6.70% and a return on equity of 42.38%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.21 EPS. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. As a group, equities analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, CEO Michael B. Jr. Petras sold 434,104 shares of Sotera Health stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $16.45, for a total transaction of $7,141,010.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gtcr Investment Xi Llc sold 6,480,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $16.33, for a total value of $105,818,400.00. Following the completion of the transaction, the director owned 22,735,301 shares in the company, valued at $371,267,465.33. This represents a 22.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 17,384,104 shares of company stock worth $284,024,511. 47.55% of the stock is currently owned by company insiders.

Institutional Trading of Sotera Health

Several large investors have recently made changes to their positions in SHC. Empowered Funds LLC grew its holdings in shares of Sotera Health by 11.1% during the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock worth $332,000 after purchasing an additional 2,845 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after purchasing an additional 43,471 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Sotera Health by 125.5% in the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after buying an additional 14,018 shares in the last quarter. Creative Planning lifted its position in shares of Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock worth $224,000 after buying an additional 2,673 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Sotera Health by 4.2% in the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock worth $3,549,000 after purchasing an additional 12,758 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.